A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction
- PMID: 11879259
- PMCID: PMC1874256
- DOI: 10.1046/j.0306-5251.2001.00032.x
A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction
Abstract
Aims: To analyse the pharmacokinetics of sildenafil citrate in patients with erectile dysfunction in order to characterize covariate relationships and assist in the development of rational dosage strategies.
Methods: A population pharmacokinetic sampling strategy was incorporated into five phase III clinical study protocols. Overall, 2077 patients, 1335 of whom received sildenafil, were asked to take an additional dose of study drug before their scheduled clinic visits on four or five occasions throughout the study duration. A single plasma sample was obtained at random times postdose (range 1--7 h), and a total of 4582 samples were assayed (average 3.4 samples per individual).
Results: For the population average patient (age 58 years; aspartate transaminase [AST], 24 IU l(-1); weight, 87 kg; not receiving CYP3A4 potential inhibitors), typical values for sildenafil (mean +/- SE) were 58.5 +/- 1.4 l h(-1) for apparent clearance (CL/F), 310 +/- 6.92 l for volume of distribution (V/F), and 2.6 +/- 0.176 h(-1) for first-order absorption constant (ka). The value for ka is associated with meal consumption within 2 h predose, at all other times ka was equivalent to an instantaneous bolus administration. The interindividual variabilities were 29% for CL/F, 20% for V/F, and 210% for ka. Over a dose range of 25--100 mg sildenafil, the pharmacokinetics exhibited dose proportionality. There was evidence of nonproportionality (40% increase on average) in relative bioavailability with respect to the 200-mg dose (P<0.001) relative to the other doses. Age, AST concentration, and co-administration with CYP3A4 potential inhibitors significantly influenced CL/F of sildenafil (P<0.001, for each relationship). For age and AST, the extent of the linear relationships (extrapolated from population average values) included a 4% decrease in CL/F for every decade increase and a 6% decrease in CL/F for every 10-unit increase, respectively. Following co-administration of CYP3A4 potential inhibitors, a 14% decrease in CL/F was estimated. Only body weight was found to significantly (P<0.001) influence V/F (a 6% increase in V/F for every 10-kg increase).
Conclusions: The pharmacokinetics of, and covariate influences on, sildenafil in patients with erectile dysfunction were shown to be consistent with those demonstrated in phase I volunteer studies.
Figures
Similar articles
-
Onset and duration of action of sildenafil for the treatment of erectile dysfunction.Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):61S-65S. doi: 10.1046/j.0306-5251.2001.00034.x. Br J Clin Pharmacol. 2002. PMID: 11879261 Free PMC article. Clinical Trial.
-
Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality.Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5S-12S. doi: 10.1046/j.0306-5251.2001.00027.x. Br J Clin Pharmacol. 2002. PMID: 11879254 Free PMC article. Clinical Trial.
-
The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):21S-30S. doi: 10.1046/j.0306-5251.2001.00029.x. Br J Clin Pharmacol. 2002. PMID: 11879256 Free PMC article. Clinical Trial.
-
Sildenafil in erectile dysfunction: a critical review.Curr Med Res Opin. 2003;19(4):241-62. doi: 10.1185/030079903125001839. Curr Med Res Opin. 2003. PMID: 12841917 Review.
-
[Erectile dysfunction--problem solved with sildenafil (Viagra)?].Internist (Berl). 1998 Dec;39(12):1232-6. doi: 10.1007/s001080050295. Internist (Berl). 1998. PMID: 10447395 Review. German. No abstract available.
Cited by
-
Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.World J Urol. 2005 Dec;23(6):374-84. doi: 10.1007/s00345-005-0022-6. Epub 2005 Nov 5. World J Urol. 2005. PMID: 16273417 Review.
-
Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis.Ann Noninvasive Electrocardiol. 2004 Jul;9(3):228-33. doi: 10.1111/j.1542-474X.2004.93554.x. Ann Noninvasive Electrocardiol. 2004. PMID: 15245338 Free PMC article.
-
Population pharmacokinetics of sildenafil in extremely premature infants.Br J Clin Pharmacol. 2019 Dec;85(12):2824-2837. doi: 10.1111/bcp.14111. Epub 2019 Dec 15. Br J Clin Pharmacol. 2019. PMID: 31475367 Free PMC article. Clinical Trial.
-
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer.J Cancer. 2017 Oct 9;8(18):3648-3656. doi: 10.7150/jca.21783. eCollection 2017. J Cancer. 2017. PMID: 29151951 Free PMC article.
-
Safety and tolerability of oral erectile dysfunction treatments in the elderly.Drugs Aging. 2005;22(4):323-38. doi: 10.2165/00002512-200522040-00005. Drugs Aging. 2005. PMID: 15839721 Review.
References
-
- Feldman HA, Goldstein I, Hatzichristou D, Krane R, McKinlay J. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61. - PubMed
-
- Linet O, Ogrine F. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Eng J Med. 1996;334:873–877. - PubMed
-
- Aloni R, Heller L, Keren O, Mendelson E, Davidoff G. Noninvasive treatment for erectile dysfunction in the neurogenically disabled population. J Sex Marital Ther. 1992;18:243–249. - PubMed
-
- Padma-Nathan H, Hellstrom W, Kaiser F. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336:1–7. - PubMed
-
- Goldstein I, Lue T, Padma-Nathan H, Rosen R, Steers W, Wicker P. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397–1404. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources